| Document Date: 2006-02-02 08:50:24
Open Document File Size: 117,25 KBShare Result on Facebook
City Cincinnati / Columbus / / Company NTP / New England Journal / / Country France / / Event FDA Phase / / Facility Genotoxicity Retreat / / IndustryTerm transportation / retroviral vector products / biologic product / contract site / / MedicalCondition leukemia / tumor / X1 disease / tumors / disease / lymphomas / human severe combined immunodeficiency / Murine leukemia / liver tumors / X-linked severe combined immunodeficiency / leukemias / NTP infectious doses / X-linked Severe Combined Immunodeficiency Syndrome / / MedicalTreatment gene therapy / Molecular Therapy / bone marrow transplants / / Organization National Institute of Health / UK Gene Therapy Advisory Committee / FDA / American Society of Gene Therapy / / Position statistician / bone marrow transplantation model for the study / Governor / academic investigator / / Product CD34 / / ProvinceOrState South Dakota / / PublishedMedium New England Journal of Medicine / / Region New England / / Technology gene therapy / gene expression / transplantation / stem cells / / URL http /
SocialTag |
CTGTAC #41, Topic II, NTP Introduction Retroviral vectors represent both the first viral vector system used for clinical gene transfer, as well as one of the most widely used in clinical trials to date. The replication